Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bezafibrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 13/20 | 1.00 |
| ▸ | PPARG known ✓ | P37231 | 3/20 | 1.00 |
| ▸ | PPARD known ✓ | Q03181 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | FABP2 | P12104 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bezafibrate SCHEMBL5077755 | 1.00 | PPARA (1.00) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Bezafibrate SCHEMBL28565716 | 0.99 | PPARA (0.98) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Bezafibrate SCHEMBL22364278 | 0.99 | PPARA (0.98) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Bezafibrate SCHEMBL3088387 | 0.99 | PPARA (0.98) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Bezafibrate SCHEMBL15156489 | 0.95 | PPARA (0.91) | PPARAPPARGPPARDALDH1A1FABP2 | |
| SCHEMBL12690942 | 0.90 | PPARA (0.82) | PPARAPPARGPPARDALDH1A1FABP2 | |
| SCHEMBL1304559 | 0.89 | PPARA (0.80) | PPARAPPARGPPARDALDH1A1FABP2 | |
| SCHEMBL14017691 | 0.89 | PPARA (0.80) | PPARAPPARGPPARDALDH1A1FABP2 | |
| SCHEMBL22943060 | 0.89 | PPARA (0.80) | PPARAPPARGPPARDALDH1A1FABP2 | |
| SCHEMBL13169312 | 0.89 | PPARA (0.80) | PPARAPPARGPPARDALDH1A1FABP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23697 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122006284-A | Continuous solution crystallization method, special device and application of bezafibrate crystals with controllable granularity | 天津科技大学 | 2026-05-12 | — | — | CN | claimed |
| CN-122010656-A | Application of oxyalkylisourea in introducing methyl and isotopically-labeled methyl | 陕西师范大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260126444-A1 | Biomarkers for Long COVID | UNIV SZEGEDI (HU) | 2026-05-07 | — | — | US | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4725479-A1 | PPAR AGONISTS FOR TREATMENT OF DISEASES ASSOCIATED WITH AATD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12582626-B2 | Methods and compositions for treating cancer | The Wister Institute of Anatomy and Biology (US) | 2026-03-24 | — | — | US | claimed |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | US GOV VETERANS AFFAIRS (US) | 2026-03-19 | — | — | US | claimed |
| EP-0419856-A2 | Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates | E.R. SQUIBB & SONS, INC. (US) | 1991-04-03 | — | — | EP | claimed |
| EP-0418814-A2 | Isoprenoid phosphinylformic acid squalene synthetase inhibitors and method for preparing the same | E.R. SQUIBB & SONS, INC. (US) | 1991-03-27 | — | — | EP | claimed |
| EP-0410409-A1 | 3,5-Dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same | E.R. SQUIBB & SONS, INC. (US) | 1991-01-30 | — | — | EP | claimed |
| EP-0409181-A2 | Phosphorus-containing squalene synthetase inhibitors and method for their preparation | E.R. SQUIBB & SONS, INC. (US) | 1991-01-23 | — | — | EP | claimed |
| US-4970221-A | 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same | E. R. SQUIBB & SONS, INC. (US) | 1990-11-13 | — | — | US | claimed |
| EP-0218928-B1 | PELLETS WITH IRREGULAR SURFACE, PROCESS FOR THEIR PREPARATION AND TABLETS CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1990-09-05 | — | — | EP | claimed |
| US-4859703-A | Lipid regulating compositions | WARNER-LAMBERT COMPANY (US) | 1989-08-22 | — | — | US | claimed |
| EP-0295637-A2 | Lipid regulating compositions | WARNER-LAMBERT COMPANY (US) | 1988-12-21 | — | — | EP | claimed |
| US-4370495-A | Process for the preparation of α-[4-(4-chlorobenzoylaminoethyl)-phenoxy]-isobutyric acid | BOEHRINGER MANNHEIM GMBH (DE) | 1983-01-25 | — | — | US | claimed |
| US-4250191-A | ADMINISTERING A PHENOXYACETIC ACID DERIVATIVE | EDWARDS K DAVID | 1981-02-10 | — | — | US | claimed |